Takeda Patent-Cliff Exposure & CMS Drug Spending Portfolio

Takeda (Cambridge, MA): 59 reconciled FDA prescription therapies (6.3% 2025 to 2030 cliff risk), $6.15B 2024 CMS Part D & Medicaid spend, and 80 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterCambridge, MA
Reconciled FDA Portfolio Therapies59
2025 to 2030 Patent-Cliff Revenue Exposure6.3%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$6.15B
2024 Medicare Part D Spend$2.95B
2024 Medicaid Spend$3.21B
California HCAI SB 17 Filings80 WAC filings (max 24.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.